Jung, Seung-Hyun <br/><br/>
Somatic mutations predict outcomes of hypomethylating therapy in patients with myelodysplastic syndrome.  [electronic resource] 

 -  Oncotarget  Aug 2016 
 - 55264-55275 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1949-2553 
<br/><br/><label>Standard No.: </label>10.18632/oncotarget.10526  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Azacitidine--therapeutic use<br/>DNA (Cytosine-5-)-Methyltransferases--genetics<br/>DNA Methylation--drug effects<br/>DNA Methyltransferase 3A<br/>DNA-Binding Proteins--genetics<br/>Dioxygenases<br/>Female<br/>Genes, p53<br/>Genes, ras<br/>Humans<br/>Male<br/>Middle Aged<br/>Mutation<br/>Myelodysplastic Syndromes--drug therapy<br/>Prognosis<br/>Proto-Oncogene Proteins--genetics<br/>Splicing Factor U2AF--genetics